East Coastsentinel

Irritable Bowel Syndrome Treatment Market to Grow at USD 3.3 Billion By 2026 |Key Player – Ironwood Pharmaceuticals, Inc.,Allergan; Astellas Pharma, Inc.

 Breaking News
  • No posts were found

Irritable Bowel Syndrome Treatment Market to Grow at USD 3.3 Billion By 2026 |Key Player – Ironwood Pharmaceuticals, Inc.,Allergan; Astellas Pharma, Inc.

November 07
02:14 2019
Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research,Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

According to a report, “ Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report By Type (IBS-C, IBS-D), By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), By Region, And Segment Forecasts, 2019 – 2026 ”, published by Grand View Research, Inc.,The global irritable bowel syndrome treatment market size is expected to reach USD 3.3 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a 10.1% CAGR during the forecast period. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient’s professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.

Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient’s professional and personal activities, and usually limits an individual’s potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.

Some of the major players are Allergan; Ironwood Pharmaceuticals, Inc.; Astellas Pharma, Inc.; AstraZeneca; Takeda Pharmaceutical Company Limited; Sebela Pharmaceuticals Inc.; Synthetic Biologics, Inc.; Ardelyx; and Bausch Health

“Would you Like/Try a Sample Report” Click the link below: https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market/request/rs1

Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.

U.S. IBS treatment Market

Further key findings from the report suggest:

  • IBS-C was the largest revenue generating segment by type in 2018 due to growing prevalence and increasing uptake of drugs such as Linzess/Constella and Amitiza

  • Linzess/Constella led the global IBS treatment market by product in 2018 due to increasing adoption of the product in major regions such as U.S., Germany, U.K., Italy, Spain, and Japan

  • North America was estimated to be the largest revenue generating region in 2018, followed by Europe. Major factors contributing to its dominant share are presence of key market players, high patient awareness, strong presence of novel products, and well-established healthcare infrastructure

  • Europe is projected to be the fastest growing region over the forecast period. Rising commercialization of products and presence of a large target population are driving the IBS treatment market

Have Any Query? Ask Our Experts for More Details on Report: https://www.grandviewresearch.com/inquiry/5654/ibb

Product Insights

Leading products developed for the treatment of symptoms of irritable bowel syndrome includeXifaxan, Linzess/Constella, Viberzi, and Amitiza. Linzess/Constella (Linaclotide) was estimated to be the largest revenue generating product segment in 2018 owing to factors such as rising adoption of the product in major regions such as U.S., U.K., Germany, Spain, Italy, and Japan. Furthermore, Linzess witnessed a significant growth rate in Japan in 2018.

Global IBS treatment Market

The Linzess/Constella segment is estimated to register the fastest growth over the course of the forecast period. Linaclotide is marketed by Ironwood and Allergan in U.S. as Linzess and is marketed by Allergan in Europe under the brand name Constella. In Japan and China, Astellas and AstraZeneca have the exclusive rights to develop and market linaclotide as Linzess respectively.

Grand View Research has segmented the IBS treatment market based on type, drug, and region:

Irritable Bowel Syndrome Treatment Type Outlook (Revenue, USD Million, 2014 – 2026)

  • IBS-C

    • Linzess/Constella

    • Amitiza

    • Others

  • IBS-D

    • Xifaxan

    • Viberzi

    • Others

Irritable Bowel Syndrome Treatment Product Outlook (Revenue, USD Million, 2014 – 2026)

  • Xifaxan

  • Linzess/Constella

  • Viberzi

  • Amitiza

  • Others

Irritable Bowel Syndrome Treatment Regional Outlook (Revenue, USD Million, 2014 – 2026)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

Request for Customization : https://www.grandviewresearch.com/request-for-customization/5654/rfc

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market